Trial abstracts in the registry — page 4
700 documents of type trial abstract.
Documents
-
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Mar 2025 -
Observational study of Epithalon in ageing over multi-year. Primary result: The Institute has not been able to obtain a protocol, a randomisation procedure or an…
24 Feb 2025 -
Randomised crossover, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 731 participants over 48 weeks. Primary result: A dose-dependent…
Moderate22 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low22 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2025 -
Event-driven kidney outcome trial, phase 3 study of Semaglutide in chronic kidney disease and type 2 diabetes randomising 3,533 participants over median 3.4 years…
High12 Feb 2025 -
Observational, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Feb 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in hfpef and obesity over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low08 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Feb 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in sleep apnoea and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low29 Jan 2025 -
Randomised crossover, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Jan 2025 -
Single-arm open-label, phase 2 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low20 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in obesity randomising 592 participants over 52 weeks. Primary result: Mean change…
Low12 Jan 2025 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over not recorded. Primary result: The Institute has identified references to a…
15 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over 52 weeks. Primary result: Substantial reduction in the…
High11 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in mash randomising 295 participants over 48 weeks. Primary result: Improvement in 62 % to 83…
Low08 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Dec 2024 -
Observational study of Semax in cognition over not recorded. Primary result: Registered in the Russian Federation on a national evidence base the Institute has not been…
20 Nov 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Nov 2024 -
Observational study of Selank in cognition over not recorded. Primary result: As for semax. The Institute records the absence of a retrievable controlled trial.
15 Nov 2024 -
Diagnostic accuracy study of Sermorelin in gh axis over single test. Primary result: Formerly marketed as a diagnostic agent; withdrawn for commercial reasons.
Moderate11 Nov 2024 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 Oct 2024 -
Observational study of Thymalin in immune modulation over not recorded. Primary result: The Institute has not obtained a retrievable protocol or analysis plan and grades…
26 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low25 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result…
Very low16 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low15 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and type 2 diabetes randomising 616 participants over 52 weeks. Primary result…
Moderate14 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Oct 2024 -
Randomised crossover, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low04 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low02 Oct 2024
page 4 of 18